Pityriasis rosea

Pityriasis rosea
Pityriasis rosea on human back and front
Classification and external resources
Specialty Dermatology, infectious disease
ICD-10 L42
ICD-9-CM 696.3
DiseasesDB 24698
MedlinePlus 000871
eMedicine derm/335 emerg/426 ped/1815
Patient UK Pityriasis rosea
MeSH D017515

Pityriasis rosea (also known as pityriasis rosea Gibert[1]) is a skin rash. It is benign but may inflict substantial discomfort in certain cases.[2] Classically, it begins with a single "herald patch" lesion, followed in 1 or 2 weeks by a generalized body rash lasting up to 12 weeks, however usually around 6 - 8.[3][4][5]

Signs and symptoms

Pityriasis rosea on human torso

The symptoms of this condition include:


The cause of pityriasis rosea is not certain, but its clinical presentation and immunologic reactions suggest a viral infection as a cause. Some believe it to be a reactivation of herpes viruses 6 and 7, which cause roseola in infants.[9][10][11][12]


A herald patch of pityriasis rosea which started before the rest of the lesion and was initially mistaken for a fungal infection

Experienced practitioners may make the diagnosis clinically.[5] If the diagnosis is in doubt, tests may be performed to rule out similar conditions such as Lyme disease, ringworm, guttate psoriasis, nummular or discoid eczema, drug eruptions, other viral exanthems.[5][13] A biopsy of the lesions will show extravasated erythrocytes within dermal papillae and dyskeratotic cells within the dermis.[5]

A set of validated diagnostic criteria for pityriasis rosea[14][15] is as follows:

A patient is diagnosed as having pityriasis rosea if:

  1. On at least one occasion or clinical encounter, he / she has all the essential clinical features and at least one of the optional clinical features, and
  2. On all occasions or clinical encounters related to the rash, he / she does not have any of the exclusional clinical features.

The essential clinical features are the following:

  1. Discrete circular or oval lesions,
  2. Scaling on most lesions, and
  3. Peripheral collarette scaling with central clearance on at least two lesions.

The optional clinical features are the following:

  1. Truncal and proximal limb distribution, with less than 10% of lesions distal to mid-upper-arm and mid-thigh,
  2. Orientation of most lesions along skin cleavage lines, and
  3. A herald patch (not necessarily the largest) appearing at least two days before eruption of other lesions, from history of the patient or from clinical observation.

The exclusional clinical features are the following:

  1. Multiple small vesicles at the centre of two or more lesions,
  2. Two or more lesions on palmar or plantar skin surfaces, and
  3. Clinical or serological evidence of secondary syphilis.


No treatment is usually required.

Oral antihistamines or topical steroids may be used to decrease itching.[5] Steroids do provide relief from itching, and improve the appearance of the rash, but they also cause the new skin that forms (after the rash subsides) to take longer to match the surrounding skin color. While no scarring has been found to be associated with the rash, scratching should be avoided. It's possible that scratching can make itching worse and an itch-scratch cycle may develop with regular scratching (that is, you itch more because you scratch, so you scratch more because you itch, and so on). Irritants such as soaps with fragrances, hot water, wool, and synthetic fabrics should be avoided; a soap containing moisturizers (such as goat's milk) may be used, however, and any generic moisturizer can help to manage over-dryness. Calamine lotion may be soothing to the skin and reduce itching. Emulsifiers should be used instead of soaps, as emulsifiers are gentler on the skin and include cleansers, eliminating the need for soap.

Direct sunlight makes the lesions resolve more quickly.[5] According to this principle, medical treatment with ultraviolet light has been used to hasten resolution,[16] though studies disagree whether it decreases itching[16] or not.[17] UV therapy is most beneficial in the first week of the eruption.[16]

Oral erythromycin was effective in treating patients.[6]

Human Herpes Virus 6 or Human Herpes Virus 7 has been hypothesized to be the cause. The antiviral drug Acyclovir can reduce length of duration and severity.[18]


In most patients, the condition lasts only a matter of weeks; in some cases it can last longer (up to six months). The disease resolves completely without long-term effects. Two percent of patients have recurrence.[19][20]


The overall prevalence of PR in the United States has been estimated to be 0.13% in men and 0.14% in women. It most commonly occurs between the ages of 10 and 35.[5] It is more common in spring.[5]

PR is not viewed as contagious,[2][21] though there have been reports of small epidemics in fraternity houses and military bases, schools and gyms.[5]

See also


  1. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
  2. 1 2 "Pityriasis rosea". American Osteopathic College of Dermatology. Retrieved 26 Jan 2010.
  3. Freedberg; et al. (2003). Fitzpatrick's Dermatology in General Medicine (6th ed.). McGraw-Hill. p. 445. ISBN 0-07-138076-0.
  4. James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. pp. 208–9. ISBN 0-7216-2921-0.
  5. 1 2 3 4 5 6 7 8 9 10 Habif, Thomas P (2004). Clinical Dermatology: A Clinical Guide to Diagnosis and Therapy (4th ed.). Mosby. pp. 246–8. ISBN 0-323-01319-8
  6. 1 2 Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L (2000). "Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial". Journal of the American Academy of Dermatology. 42 (2 Pt 1): 241–4. doi:10.1016/S0190-9622(00)90132-4. PMID 10642679.
  7. 1 2 3 4 5 6 "Pityriasis rosea". American Academy of Dermatology. 2003. Retrieved 2009-06-04.
  8. Tay YK, Goh CL (1999). "One-year review of pityriasis rosea at the National Skin Centre, Singapore". Annals of the Academy of Medicine, Singapore. 28 (6): 829–31. PMID 10672397.
  9. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A (2014). "Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea". Journal of the American Academy of Dermatology. 71 (1): 198–9. doi:10.1016/j.jaad.2014.02.023. PMID 24947696.
  10. http://www.dermnetnz.org/viral/pityriasis-rosea.html[]
  11. Pityriasis Rosea at eMedicine
  12. Cynthia M. Magro; A. Neil Crowson; Martin C. Mihm (2007). The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin. John Wiley and Sons. pp. 36–. ISBN 978-0-471-69598-1. Retrieved 10 November 2010.
  13. Horn T, Kazakis A (1987). "Pityriasis rosea and the need for a serologic test for syphilis". Cutis. 39 (1): 81–2. PMID 3802914.
  14. Chuh AA (2003). "Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity". Journal of the European Academy of Dermatology and Venereology. 17 (1): 101–3. doi:10.1046/j.1468-3083.2003.00519_4.x. PMID 12602987.
  15. Chuh A, Zawar V, Law M, Sciallis G (2012). "Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria". Infectious Disease Reports. 4 (1): e12. doi:10.4081/idr.2012.e12. PMC 3892651Freely accessible. PMID 24470919.
  16. 1 2 3 Arndt KA, Paul BS, Stern RS, Parrish JA (1983). "Treatment of pityriasis rosea with UV radiation". Archives of Dermatology. 119 (5): 381–2. doi:10.1001/archderm.119.5.381. PMID 6847217.
  17. Leenutaphong V, Jiamton S (1995). "UVB phototherapy for pityriasis rosea: a bilateral comparison study". Journal of the American Academy of Dermatology. 33 (6): 996–9. doi:10.1016/0190-9622(95)90293-7. PMID 7490372.
  18. Ganguly S (2014). "A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea". Journal of Clinical and Diagnostic Research. 8 (5): YC01–4. doi:10.7860/JCDR/2014/8140.4360. PMC 4080052Freely accessible. PMID 24995231.
  19. Kempf W, Adams V, Kleinhans M, Burg G, Panizzon RG, Campadelli-Fiume G, Nestle FO (1999). "Pityriasis rosea is not associated with human herpesvirus 7". Archives of Dermatology. 135 (9): 1070–2. doi:10.1001/archderm.135.9.1070. PMID 10490111.
  20. Chuang TY, Ilstrup DM, Perry HO, Kurland LT (1982). "Pityriasis rosea in Rochester, Minnesota, 1969 to 1978". Journal of the American Academy of Dermatology. 7 (1): 80–9. doi:10.1016/s0190-9622(82)80013-3. PMID 6980904.
  21. "Pityriasis rosea". DERMAdoctor.com. Retrieved 26 Jan 2010.
This article is issued from Wikipedia - version of the 5/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.